|
|
Post by robsacher on Nov 1, 2016 13:28:07 GMT -5
|
|
|
|
Post by slugworth008 on Nov 1, 2016 13:36:16 GMT -5
Hhmmm, maybe it's worth reaching out to Bernie about the Afrezza story??? |
|
|
|
Post by dictatorsaurus on Nov 1, 2016 13:45:48 GMT -5
The only thing that can help Afrezza is an increase in sales. The drug is still virtually unknown. And the few that know about it and still on the fence and most endos are not prescribing. You need money to promote and advertise and you need to advertise to make money. Tricky situation. |
|
|
|
Post by peppy on Nov 1, 2016 13:47:28 GMT -5
|
|
|
|
Post by figglebird on Nov 1, 2016 13:54:03 GMT -5
I think this has been the central issue - diabetes is not going to beat itself - those on the forefront have been losing the war for a century empowered by the profit margins of the insulin mob - Al Mann understood this and hedged his property with the 50m put - as insulin becomes cheaper, a more viable delivery system will emerge as not only a more personalized option for gererations to come but a cost effective one... At this point everyone should understand that Afrezza uses/needs more insulin due to its bioavailability being between 38-50pct.... SC's bioavailability is at 80 pct.
This is a fundamental obstacle that will change overtime as it gets more attention...
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Nov 1, 2016 13:56:01 GMT -5
I think this has been the central issue - diabetes is not going to beat itself - those on the forefront have been losing the war for a century empowered by the profit margins of the insulin mob - Al Mann understood this and hedged his property with the 50m put - as insulin becomes cheaper, a more viable delivery system will emerge as not only a more personalized option for gererations to come but a cost effective one... At this point everyone should understand that Afrezza uses/needs more insulin due to its bioavailability being between 38-50pct.... SC's bioavailability is at 80 pct. This is a fundamental obstacle that will change overtime as it gets more attention... lol...2 billion invested and you speak of the 50 m put. you must be thinking great. |
|
|
|
Post by peppy on Nov 1, 2016 13:59:04 GMT -5
I think this has been the central issue - diabetes is not going to beat itself - those on the forefront have been losing the war for a century empowered by the profit margins of the insulin mob - Al Mann understood this and hedged his property with the 50m put - as insulin becomes cheaper, a more viable delivery system will emerge as not only a more personalized option for gererations to come but a cost effective one... At this point everyone should understand that Afrezza uses/needs more insulin due to its bioavailability being between 38-50pct.... SC's bioavailability is at 80 pct. This is a fundamental obstacle that will change overtime as it gets more attention... figgle, afrezza is able to use more insulin. you have it backwards. able because of the phase one response that the diabetic does not get with insulin analogues subq. Afrezza is two signaling systems in one insulin
|
|
|
|
Post by zuegirdor on Nov 1, 2016 14:39:21 GMT -5
I think this has been the central issue - diabetes is not going to beat itself - those on the forefront have been losing the war for a century empowered by the profit margins of the insulin mob - Al Mann understood this and hedged his property with the 50m put - as insulin becomes cheaper, a more viable delivery system will emerge as not only a more personalized option for gererations to come but a cost effective one... At this point everyone should understand that Afrezza uses/needs more insulin due to its bioavailability being between 38-50pct.... SC's bioavailability is at 80 pct. This is a fundamental obstacle that will change overtime as it gets more attention... figgle, afrezza is able to use more insulin. you have it backwards. able because of the phase one response that the diabetic does not get with insulin analogues subq. Afrezza is two signaling systems in one insulin
Thanks Peppy! Just when I thought I had a handle on all things Afrezza, you point out a gap in my understanding. Part of the inhaled dose is "spent" suppressing hepatic glucose release (glycogen). Would like to see more data on this but seems reasonable! Here I thought that all that "wasted" insulin was swallowed or inactivated by mucous etc...(though some no doubt is) |
|
|
|
Post by cjm18 on Nov 1, 2016 15:21:46 GMT -5
If the profits of the insulin giants are being squeezed then maybe these giants will be more willing to shell out top dollar for a superior insulin that could potentially be priced at a premium to inferior insulin.
|
|
|
|
Post by silentknight on Nov 1, 2016 15:59:51 GMT -5
If the profits of the insulin giants are being squeezed then maybe these giants will be more willing to shell out top dollar for a superior insulin that could potentially be priced at a premium to inferior insulin. This has been tried with SNY. It doesn't work. Afrezza needs a price reduction and a better label, not more of the same failed marketing strategy that we've seen already. |
|
|
|
Post by cjm18 on Nov 1, 2016 16:53:53 GMT -5
If the profits of the insulin giants are being squeezed then maybe these giants will be more willing to shell out top dollar for a superior insulin that could potentially be priced at a premium to inferior insulin. This has been tried with SNY. It doesn't work. Afrezza needs a price reduction and a better label, not more of the same failed marketing strategy that we've seen already. My key word was potentially. Afrezza needs to be proven to be superior first. Via label or data or what not. |
|
|
|
Post by compound26 on Nov 1, 2016 18:49:24 GMT -5
|
|
|
|
Post by peppy on Nov 2, 2016 12:25:05 GMT -5
rob, consider this spin on a straight forward story of data. "Will continuous glucose monitors save Mannkind? Afrezza users think they should. Let's look at the evidence.
|
|
|
|
Post by robsacher on Nov 2, 2016 12:44:00 GMT -5
That's a good idea, probably after the election.
|
|
|
|
Post by gtay87 on Nov 2, 2016 12:45:19 GMT -5
rob, consider this spin on a straight forward story of data. "Will continuous glucose monitors save Mannkind? Afrezza users think they should. Let's look at the evidence.
Most insurance won't reimburse or else will struggle to refuse to reimburse CGMs as well. |
|
